Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study

Sara Bottiroli, Roberto De Icco, Gloria Vaghi, +7

The Journal of Headache and Pain

COVID‐19 in patients with myasthenia gravis: Epidemiology and disease course

Pietro Businaro, Gloria Vaghi, Enrico Marchioni, +12

Muscle & Nerve

Setting higher standards for migraine prevention: A position statement of the International Headache Society

Simona Sacco, Messoud Ashina, Hans‐Christoph Diener, +15

Cephalalgia

Migraine FreedomPharmacotherapyPre-clinical PharmacologyNon-pharmacological InterventionClinical Trials +16

Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

Edoardo Caronna, Victor J Gallardo, Gabriella Egeo, +63

Journal of Neurology Neurosurgery & Psychiatry

Correlation of Frontal Atrophy and CSF Tau Levels With Neuropsychiatric Symptoms in Patients With Cognitive Impairment: A Memory Clinic Experience

Matteo Cotta Ramusino, Giulia Perini, Gloria Vaghi, +7

Frontiers in Aging Neuroscience

Direct antivirals and cognitive impairment in hepatitis C: a clinical-neurophysiologic study

Gloria Vaghi, Benedetta Gori, Gionata Strigaro, +7

Journal of NeuroVirology

Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial

Roberto De Icco, Gloria Vaghi, Marta Allena, +11

The Journal of Headache and Pain

Who cares about migraine? Pathways and hurdles in the European region - access to care III

Gloria Vaghi, Roberto De Icco, Cristina Tassorelli, +3

The Journal of Headache and Pain

Searching for the Predictors of Response to BoNT-A in Migraine Using Machine Learning Approaches

Daniele Martinelli, Maria Magdalena Pocora, Roberto De Icco, +5

Toxins

Chronic MigraineCluster HeadacheEngineeringMachine LearningData Science +11

Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study

Valeria Caponnetto, Antonio Russo, Marcello Silvestro, +30

CNS Drugs